LRRFIP2: A Potential Drug Target and Biomarker (G9209)

Target Name: LRRFIP2

NCBI ID: G9209

LRRFIP2

LRRFIP2: A Potential Drug Target and Biomarker

LRRFIP2 (LRR FLII-interacting protein 2) is a protein that has been identified as a potential drug target and biomarker. It is a key regulator of the fibroblast, a cell that plays a crucial role in the production of extracellular matrix (ECM) components, including collagen. The fibroblast is also responsible for maintaining the three-dimensional structure of ECM and contribute to tissue repair and regeneration. LRRFIP2 has been shown to play a role in the regulation of ECM maturation and degradation, as well as in the regulation of cellular processes such as cell adhesion, migration, and invasion.

The Drosfensome

The Drosfensome is a protein complex that is involved in the regulation of the actin cytoskeleton in the fruit fly. It consists of the protein Drosfensin-1, Drosfensin-2, and Drosfensin-3, as well as the protein F-actinin. The Drosfensome is responsible for the regulation of cell movement, as well as the formation of the actin cytoskeleton. It is also involved in the regulation of the cytoskeleton in the development and progression of tissues.

LRRFIP2 and Drosfensome

The LRRFIP2 protein has been shown to interact with the Drosfensome protein. This interaction allows LRRFIP2 to regulate the activity of the Drosfensome. LRRFIP2 has been shown to inhibit the activity of the Drosfensome, which results in the relaxation of the actin cytoskeleton and the formation of new actin filaments. This is important for the regulation of cell movement and the formation of tissues.

LRRFIP2 and Fibroblast

LRRFIP2 has also been shown to regulate the activity of the fibroblast, a cell that plays a crucial role in the production of ECM components. The fibroblast is responsible for the production of collagen, which is a key component of the extracellular matrix. LRRFIP2 has been shown to regulate the activity of the fibroblast by the inhibition of the genes that are involved in the production of collagen. This is important for the regulation of tissue repair and regeneration.

LRRFIP2 and Cancer

LRRFIP2 has also been shown to be involved in the regulation of cancer cell growth and metastasis. It has been shown to inhibit the activity of the genes that are involved in cell growth and the development of cancer. This is important for the regulation of cancer cell progression and the development of new treatments.

Conclusion

LRRFIP2 is a protein that has been shown to play a role in the regulation of various cellular processes, including cell growth, migration, and actin cytoskeleton formation. It has also been shown to interact with the Drosfensome, a protein that is involved in the regulation of cell movement and the actin cytoskeleton. LRRFIP2 may be a potential drug target and biomarker for the regulation of various diseases, including cancer. Further research is needed to fully understand the role of LRRFIP2 in these processes and to develop new treatments.

Protein Name: LRR Binding FLII Interacting Protein 2

Functions: May function as activator of the canonical Wnt signaling pathway, in association with DVL3, upstream of CTNNB1/beta-catenin. Positively regulates Toll-like receptor (TLR) signaling in response to agonist probably by competing with the negative FLII regulator for MYD88-binding

The "LRRFIP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRRFIP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets